Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation

Mortality in relation to smoking: 50 years' observations on male British doctors

Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004) · BMJ · doi:10.1136/bmj.38142.554479.ae · Cited by 2,920 · cited 1× · see citing works

Drug Addiction and Its Underlying Neurobiological Basis: Neuroimaging Evidence for the Involvement of the Frontal Cortex

Goldstein, R. Z., & Volkow, N. D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1642 · Cited by 2,667 · see citing works

Shape of the relapse curve and long-term abstinence among untreated smokers

Hughes, J. R., Keely, J., & Naud, S. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00540.x · Cited by 1,414 · see citing works

Mortality in relation to smoking: 40 years' observations on male British doctors

Doll, R., Peto, R., Wheatley, K., Gray, R., & Sutherland, I. (1994) · BMJ · doi:10.1136/bmj.309.6959.901 · Cited by 1,321 · see citing works

Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine

Picciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320 · see citing works

Estimates of global mortality attributable to smoking in 2000

Ezzati, M., & Lopez, A. D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14338-3 · Cited by 1,247 · see citing works

The Mortality of Doctors in Relation to Their Smoking Habits

Doll, R., & Hill, A. B. (1954) · BMJ · doi:10.1136/bmj.1.4877.1451 · Cited by 924 · see citing works

A Clinical Practice Guideline for Treating Tobacco Use and Dependence: A US Public Health Service Report

Panel, S. T. T. U. A. D. C. P. G. (2000) · JAMA · doi:10.1001/jama.283.24.3244 · Cited by 827 · see citing works

Nicotine Activation of α4* Receptors: Sufficient for Reward, Tolerance, and Sensitization

Tapper, A. R., McKinney, S. L., Nashmi, R., Schwarz, J., Deshpande, P., Labarca, C., Whiteaker, P., Marks, M. J., Collins, A. C., & Lester, H. A. (2004) · Science · doi:10.1126/science.1099420 · Cited by 686 · see citing works

Role of dopamine in the behavioural actions of nicotine related to addiction

Chiara, G. D. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00122-9 · Cited by 680 · see citing works

Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors

Maskos, U., Molles, B. E., Pons, S., Besson, M., Guiard, B. P., Guilloux, J.-P., Evrard, A., Cazala, P., Cormier, A., Mameli-Engvall, M., et al. (2005) · Nature · doi:10.1038/nature03694 · Cited by 566 · see citing works

Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors

Luetje, C., & Patrick, J. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-03-00837.1991 · Cited by 558 · see citing works

Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533 · see citing works

Effect of smokeless tobacco (snus) on smoking and public health in Sweden

Foulds, J., Ramstrom, L., Burke, M., & Fagerström, K. (2003) · Tobacco Control · doi:10.1136/tc.12.4.349 · Cited by 471 · see citing works

Cellular mechanisms of nicotine addiction

Dani, J. A., & De Biasi, M. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00652-9 · Cited by 408 · see citing works

[16] Electrophysiologic recordings from Xenopus oocytes

Stühmer, W. (1998) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(98)93019-1 · Cited by 358 · see citing works

Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities

HUGHES, J. R., HIGGINS, S. T., & BICKEL, W. K. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03744.x · Cited by 312 · see citing works

Clinical Pharmacology of Nicotine

Benowitz, N. L. (1986) · Annual Review of Medicine · doi:10.1146/annurev.med.37.1.21 · Cited by 285 · see citing works

Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit

Papke, R. L., & Heinemann, S. F. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09896-7 · Cited by 259 · see citing works

Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone

Rose, J. E., Behm, F. M., Westman, E. C., Levin, E. D., STEIN, R. M., & Ripka, G. V. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.105 · Cited by 248 · see citing works

[19] Electrophysiological recording from Xenopus oocytes

Stühmer, W. (1992) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(92)07021-f · Cited by 243 · see citing works

Blockade of Nicotine Self-Administration with Nicotinic Antagonists in Rats

Watkins, S. S., Epping-Jordan, M. P., Koob, G. F., & Markou, A. (1999) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00226-3 · Cited by 229 · see citing works

Clinical Pharmacology of Nicotine

Benowitz, N. L. (1986) · Annual Review of Medicine · doi:10.1146/annurev.me.37.020186.000321 · Cited by 211 · see citing works

METABOLISM AND DISPOSITION OF VARENICLINE, A SELECTIVE α4β2 ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, IN VIVO AND IN VITRO

Obach, R. S., Reed‐Hagen, A. E., Krueger, S. S., Obach, B. J., O’Connell, T. N., Zandi, K. S., Miller, S., & Coe, J. W. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006767 · Cited by 199 · see citing works

Cytisine for Smoking Cessation

Etter, J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1553 · Cited by 195 · see citing works

A comparison of psychological and pharmacological treatment in smoking cessation

Fagerstr�m, K. O. (1982) · Journal of Behavioral Medicine · doi:10.1007/bf00846161 · Cited by 179 · see citing works

Nicotine dependence

Malin, D. H. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00699-2 · Cited by 167 · see citing works

Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy.

Rose, J. E., Behm, F. M., & Westman, E. C. (1998) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.6.3.331 · Cited by 159 · see citing works

Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain

Anderson, D. J., & Arnerić, S. P. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90200-3 · Cited by 158 · see citing works

Effect of nicotine chewing gum in smoking cessation. A randomized, placebo-controlled, double-blind study

Hjalmarson, Å. (1984) · JAMA · doi:10.1001/jama.252.20.2835 · Cited by 155 · see citing works

Nicotine–mecamylamine treatment for smoking cessation: The role of pre-cessation therapy.

Rose, J. E., Behm, F. M., & Westman, E. C. (1998) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.6.3.331 · Cited by 146 · see citing works

Synthesis and antiviral evaluation of benzimidazoles, quinoxalines and indoles from dehydroabietic acid

Fonseca, T., Gigante, B., Marques, M. M., Gilchrist, T. L., & Clercq, E. D. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.10.013 · Cited by 143 · see citing works

Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline

Reavill, C. A., Walther, B., Stolerman, I. P., & Testa, B. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90022-j · Cited by 141 · see citing works

WHO Framework Convention on Tobacco Control: a global "good" for public health.

Taylor, A. L., & Bettcher, D. W. (2000) · PubMed · Cited by 125 · see citing works

The binding of L-[3H]nicotine to a single class of high affinity sites in rat brain membranes.

Lippiello, P. M., & Fernandes, K. G. (1986) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10280-0 · Cited by 123 · see citing works

Anabaseine Is a Potent Agonist on Muscle and Neuronal Alpha-Bungarotoxin-Sensitive Nicotinic Receptors

Kem, W. R., Mahnir, V. M., Papke, R. L., & Lingle, C. J. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37134-4 · Cited by 119 · see citing works

Nicotinic Acetylcholine Receptors as Drug Targets

Hogg, R. C., & Bertrand, D. (2004) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007043482507 · Cited by 113 · see citing works

Nicotinic receptor function determined by stimulation of rubidium efflux from mouse brain synaptosomes.

Marks, M. J., Farnham, D. A., Grady, S. R., & Collins, A. C. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10175-4 · Cited by 112 · see citing works

Synthesis of Analogues of (−)-Cytisine for in Vivo Studies of Nicotinic Receptors Using Positron Emission Tomography

Marrière, E., Rouden, J., Tadino, V., & Lasne, M. (2000) · Organic Letters · doi:10.1021/ol005685m · Cited by 112 · see citing works

Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users

Quinn, D. I., Wodak, A., & Day, R. O. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733050-00003 · Cited by 104 · see citing works

Single‐Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers

Faessel, H. M., Smith, B. J., Gibbs, M. A., Gobey, J. S., Clark, D. J., & Burstein, A. H. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006290669 · Cited by 104 · see citing works

Dehydrobenzol und Cyclopentadien

Wittig, G., & Knauss, E. (1958) · Chemische Berichte · doi:10.1002/cber.19580910502 · Cited by 101 · see citing works

Nicotine Gum, 2 and 4 mg, for Nicotine Dependence

Herrera, N., Franco, R., Herrera, L., Partidas, A., Rolando, R., & Fagerström, K. O. (1995) · Chest · doi:10.1378/chest.108.2.447 · Cited by 101 · see citing works

Some studies on cytisine and its methylated derivatives

Barlow, R. B., & McLeod, L. J. (1969) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1969.tb07977.x · Cited by 99 · see citing works

Aromatic nitration with nitric acid and trifluoromethanesulfonic acid

Coon, C. L., Blucher, W. G., & Hill, M. E. (1973) · The Journal of Organic Chemistry · doi:10.1021/jo00964a007 · Cited by 94 · see citing works

Cytisine derivatives as ligands for neuronal nicotine receptors and with various pharmacological activities

Boido, C. C., Tasso, B., Boido, V., & Sparatore, F. (2003) · Il Farmaco · doi:10.1016/s0014-827x(03)00017-x · Cited by 93 · see citing works

Central nicotinic receptor ligands and pharmacophores

Glennon, R. A., & Dukat, M. (2000) · Pharmaceutica Acta Helvetiae · doi:10.1016/s0031-6865(99)00022-9 · Cited by 91 · see citing works

Differential Reinforcing Effects of Cocaine and GBR-12909: Biochemical Evidence for Divergent Neuroadaptive Changes in the Mesolimbic Dopaminergic System

Tella, S. R., Ladenheim, B., Andrews, A. M., Goldberg, S. R., & Cadet, J. L. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-23-07416.1996 · Cited by 88 · see citing works

Design of Ligands for the Nicotinic Acetylcholine Receptors:The Quest for Selectivity

Bunnelle, W. H., Dart, M. M. J., & Schrimpf, M. R. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043451438 · Cited by 86 · see citing works

3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation

Coe, J. W., Brooks, P. R., Wirtz, M. C., Bashore, C. G., Bianco, K. E., Vetelino, M. G., Arnold, E. P., Lebel, L. A., Fox, C. B., Tingley, F. D., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.08.035 · Cited by 73 · see citing works

Swedish Match Company, Swedish snus and public health: a harm reduction experiment in progress?

Henningfield, J. E., & Fagerström, K. O. (2001) · Tobacco Control · doi:10.1136/tc.10.3.253 · Cited by 71 · see citing works

In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (−)-cytisine

Coe, J. W., Vetelino, M. G., Bashore, C. G., Wirtz, M. C., Brooks, P. R., Arnold, E. P., Lebel, L. A., Fox, C. B., Sands, S. B., Davis, T. I., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.04.036 · Cited by 69 · see citing works

New treatments for smoking cessation

Hughes, J. R. (2000) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.3.143 · Cited by 68 · see citing works

Formation of 3-Halobenzyne: Solvent Effects and Cycloaddition Adducts

Coe, J. W., Wirtz, M. C., Bashore, C. G., & Candler, J. (2004) · Organic Letters · doi:10.1021/ol049655l · Cited by 64 · see citing works

Epibatidine structure–activity relationships

Carroll, F. I. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.02.007 · Cited by 63 · see citing works

Synthesis of UB-165: A novel nicotinic ligand and anatoxin-a/epibatidine hybrid

Wright, E., Gallagher, T. C., Sharples, C. G. V., & Wonnacott, S. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(97)10090-7 · Cited by 62 · see citing works

Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine

Mansbach, R. S., Chambers, L. K., & Rovetti, C. C. (2000) · Psychopharmacology · doi:10.1007/s002130050047 · Cited by 50 · see citing works

Investigation of the reactivity of palladium(0) complexes with nitroso compounds: relevance to the palladiumphenanthroline-catalysed carbonylation reactions of nitroarenes

Gallo, E., Ragaini, F., Cenini, S., & Demartin, F. (1999) · Journal of Organometallic Chemistry · doi:10.1016/s0022-328x(99)00263-6 · Cited by 49 · see citing works

Moist snuff in Sweden—tradition and evolution

Nordgren, P., & Ramström, L. (1990) · British Journal of Addiction · doi:10.1111/j.1360-0443.1990.tb03435.x · Cited by 47 · see citing works

Cytisine derivatives as high affinity nAChR ligands: synthesis and comparative molecular field analysis

Nicolotti, O., Boido, C. C., Sparatore, F., & Carotti, A. (2002) · Il Farmaco · doi:10.1016/s0014-827x(02)01216-8 · Cited by 46 · see citing works

Intrathecal Morphine and Heroin in Humans

Kotob, H. I. M., Hand, C. W., Moore, A., Evans, P. J., Wells, J., Rubin, A. P., & McQuay, H. J. (1986) · Anesthesia & Analgesia · doi:10.1213/00000539-198607000-00002 · Cited by 32 · see citing works

EXPERIMENTS IN THE VERATROLE AND QUINOXALINE GROUPS

EHRLICH, J., & Bogert, M. T. (1947) · The Journal of Organic Chemistry · doi:10.1021/jo01168a006 · Cited by 31 · see citing works

Preparation of 1,5-Methano-2,3,4,5- tetrahydro-1H-3-benzazepine via Pd-Catalyzed Cyclization

Singer, R. A., McKinley, J. D., Barbe, G., & Farlow, R. A. (2004) · Organic Letters · doi:10.1021/ol049316s · Cited by 28 · see citing works

Rational Design of Receptor Partial Agonists and Possible Mechanisms of Receptor Partial Activation: A Theory

Zhu, B. T. (1996) · Journal of Theoretical Biology · doi:10.1006/jtbi.1996.0130 · Cited by 27 · see citing works

The Distribution of Neuronal Nicotinic Acetylcholine Receptors

Sargent, P. B. (2000) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-57079-7_7 · Cited by 22 · see citing works

Über Cytisin und Ulexin

Partheil, A. (1894) · Archiv der Pharmazie · doi:10.1002/ardp.18942320302 · Cited by 22 · see citing works

Synthesis and pharmacological activity of 2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepines

Mazzocchi, P. H., & Stahly, B. C. (1979) · Journal of Medicinal Chemistry · doi:10.1021/jm00190a020 · Cited by 21 · see citing works

A General Route to the Synthesis of 1,5-Methano- and 1,5-Ethano- 2,3,4,5-tetrahydro-1H-3-benzazepines

O’Donnell, C. J., Singer, R. A., Brubaker, J. D., & McKinley, J. D. (2004) · The Journal of Organic Chemistry · doi:10.1021/jo049122q · Cited by 14 · see citing works

3-D-QSAR of N-substituted 4-amino-3,3-dialkyl-2(3H)-furanone GABA receptor modulators using molecular field analysis and receptor surface modelling study

Ghoshal, N., & Mukherjee, P. K. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.10.006 · Cited by 14 · see citing works

Substituent effects and homobenzylic conjugation in benzonorbornen-2(exo)-yl p-bromobenzenesulfonate solvolyses

Tanida, H., Ishitobi, H., Irie, T., & Tsushima, T. (1969) · Journal of the American Chemical Society · doi:10.1021/ja01044a034 · Cited by 13 · see citing works

Synthesis and analgetic activity of 1,2,3,4,5,6-hexahydro-1,6-methano-3-benzazocines

Mazzocchi, P. H., & Harrison, A. M. (1978) · Journal of Medicinal Chemistry · doi:10.1021/jm00200a021 · Cited by 9 · see citing works

Synthesis of 2,3,4,5-Tetrahydro-1,5-methano-1H-3-benzazepine via Oxidative Cleavage and Reductive Amination Strategies

Coe, J. W., Singer, R. A., Brooks, P. R., Caron, S., Ng, K., Vazquez, E., Vetelino, M. G., Watson, H., Whritenour, D. C., & Wirtz, M. C. (2004) · Synthesis · doi:10.1055/s-2004-829135 · Cited by 8 · see citing works

2,3‐Pyrazinedicarboxylic Acid

Jones, R. G., & McLaughlin, K. C. (2003) · Organic Syntheses · doi:10.1002/0471264180.os030.32 · Cited by 4 · see citing works

How were new medicines discovered?

Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812 · see citing works

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology

Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,607 · see citing works

Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling

Lüscher, C., & Malenka, R. C. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.017 · Cited by 1,105 · see citing works

Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics

Benowitz, N. L. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094742 · Cited by 979 · see citing works

Modern advances in heterocyclic chemistry in drug discovery

Taylor, A. P., Robinson, R. P., Fobian, Y. M., Blakemore, D. C., Jones, L. H., & Fadeyi, O. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00936k · Cited by 895 · see citing works

An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles

Baumann, M., & Baxendale, I. R. (2013) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.9.265 · Cited by 842 · see citing works

Innate C-H trifluoromethylation of heterocycles

Ji, Y., Brückl, T., Baxter, R. D., Fujiwara, Y., Seiple, I. B., Su, S., Blackmond, D. G., & Baran, P. S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109059108 · Cited by 760 · see citing works

Nicotine receptor partial agonists for smoking cessation

Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747 · see citing works

Natural product and natural product derived drugs in clinical trials

Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Natural Product Reports · doi:10.1039/c4np00064a · Cited by 605 · see citing works

Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors

Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558 · see citing works

Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533 · see citing works

The discovery of first-in-class drugs: origins and evolution

Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514 · see citing works

It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood

PICCIOTTO, M., ADDY, N., MINEUR, Y., & BRUNZELL, D. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.12.005 · Cited by 451 · see citing works

Nicotine receptor partial agonists for smoking cessation

Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433 · see citing works

Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation

Rollema, H., Coe, J. W., Chambers, L. K., Hurst, R. S., Stahl, S. M., & Williams, K. E. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.05.003 · Cited by 400 · see citing works

Smoking Cessation With Varenicline, a Selective α4β2 Nicotinic Receptor Partial Agonist: Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up

Nides, M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1561 · Cited by 390 · see citing works

Neurobiology of Nicotine Addiction: Implications for Smoking Cessation Treatment

Benowitz, N. L. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.01.015 · Cited by 385 · see citing works

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation

Oncken, C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1571 · Cited by 380 · see citing works

Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking

Steensland, P., Simms, J. A., Holgate, J. Y., Richards, J. K., & Bartlett, S. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705368104 · Cited by 368 · see citing works

Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease

Rigotti, N. A., Pipe, A., Benowitz, N. L., Arteaga, C., Garza, D., & Tonstad, S. (2010) · Circulation · doi:10.1161/circulationaha.109.869008 · Cited by 364 · see citing works

Nicotine binding to brain receptors requires a strong cation–π interaction

Xiu, X., Puskar, N. L., Shanata, J. A. P., Lester, H. A., & Dougherty, D. A. (2009) · Nature · doi:10.1038/nature07768 · Cited by 363 · see citing works

Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century

Laniado-Laborı́n, R. (2009) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph6010209 · Cited by 362 · see citing works

Pharmacological interventions for promoting smoking cessation during pregnancy

Coleman, T., Chamberlain, C., Davey, M.-A., Cooper, S. E., & Leonardi-Bee, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010078.pub2 · Cited by 357 · see citing works

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

Aubin, H.-J., Bobak, A., Britton, J. R., Oncken, C., Billing, C. B., Gong, J., Williams, K. E., & Reeves, K. R. (2008) · Thorax · doi:10.1136/thx.2007.090647 · Cited by 344 · see citing works

Impact of Physical Exercise on Substance Use Disorders: A Meta-Analysis

Wang, D., Wang, Y., Wang, Y., Li, R., & Zhou, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110728 · Cited by 340 · see citing works

Ion Channels as Therapeutic Targets: A Drug Discovery Perspective

Bagal, S. K., Brown, A. D., Cox, P. J., Omoto, K., Owen, R. M., Pryde, D. C., Sidders, B. S., Skerratt, S. E., Stevens, E. B., Storer, R. I., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3011433 · Cited by 320 · see citing works

Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers

McKee, S. A., Harrison, E. L. R., O’Malley, S. S., Krishnan‐Sarin, S., Shi, J. M., Tetrault, J. M., Picciotto, M. R., Petrakis, I. L., Estevez, N., & Balchunas, E. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.029 · Cited by 302 · see citing works

Cigarette smoking: An undertreated risk factor for cardiovascular disease

Erhardt, L. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.01.007 · Cited by 284 · see citing works

Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis

Mineur, Y. S., & Picciotto, M. R. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.004 · Cited by 277 · see citing works

Indolizidine and quinolizidine alkaloids

Michael, J. P. (2007) · Natural Product Reports · doi:10.1039/b509525p · Cited by 264 · see citing works

Cytisine versus Nicotine for Smoking Cessation

Walker, N. K., Howe, C., Glover, M., McRobbie, H. J., Barnes, J., Nosa, V. H., Parag, V., Bassett, B., & Bullen, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407764 · Cited by 260 · see citing works

Strength of urges to smoke as a measure of severity of cigarette dependence: comparison with the Fagerström Test for Nicotine Dependence and its components

Fidler, J. A., Shahab, L., & West, R. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.03226.x · Cited by 242 · see citing works

Smoking and diabetes: dangerous liaisons and confusing relationships

Campagna, D., Alamo, A., Pino, A. D., Russo, C., Calogero, A. E., Purrello, F., & Polosa, R. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0482-2 · Cited by 229 · see citing works

Direct α-C–H bond functionalization of unprotected cyclic amines

Chen, W., Ma, L., Paul, A., & Seidel, D. (2017) · Nature Chemistry · doi:10.1038/nchem.2871 · Cited by 223 · see citing works

Varenicline improves mood and cognition during smoking abstinence

Patterson, F., Jepson, C., Strasser, A. A., Loughead, J., Perkins, K. A., Gur, R. C., Frey, J. M., Siegel, S., & Lerman, C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.028 · Cited by 222 · see citing works

Effect of Varenicline on Smoking Cessation Through Smoking Reduction

Ebbert, J. O., Hughes, J. R., West, R., Rennard, S. I., Russ, C., McRae, T. D., Treadow, J., Yu, C., Dutro, M. P., & Park, P. W. (2015) · JAMA · doi:10.1001/jama.2015.280 · Cited by 210 · see citing works

Effects of Varenicline on Smoking Cessation in Patients With Mild to Moderate COPD

Tashkin, D. P., Rennard, S. I., Hays, J. T., Ma, W., Lawrence, D., & Lee, T. C. (2010) · CHEST Journal · doi:10.1378/chest.10-0865 · Cited by 209 · see citing works

Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt

West, R., Baker, C. L., Cappelleri, J. C., & Bushmakin, A. G. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1041-3 · Cited by 203 · see citing works

METABOLISM AND DISPOSITION OF VARENICLINE, A SELECTIVE α4β2 ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, IN VIVO AND IN VITRO

Obach, R. S., Reed‐Hagen, A. E., Krueger, S. S., Obach, B. J., O’Connell, T. N., Zandi, K. S., Miller, S., & Coe, J. W. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006767 · Cited by 199 · see citing works

Cytisine for Smoking Cessation

Etter, J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1553 · Cited by 195 · see citing works

Effects of Nicotine in Experimental Animals and Humans: An Update on Addictive Properties

Foll, B. L., & Goldberg, S. R. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_12 · Cited by 194 · see citing works

α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson’s Disease

Quik, M., & Wonnacott, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003269 · Cited by 194 · see citing works

Pharmacological interventions for promoting smoking cessation during pregnancy

Claire, R., Chamberlain, C., Davey, M.-A., Cooper, S. E., Berlin, I., Leonardi-Bee, J., & Coleman, T. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010078.pub3 · Cited by 188 · see citing works

Nicotine receptor partial agonists for smoking cessation

Cahill, K., Stead, L. F., & Lancaster, T. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub5 · Cited by 187 · see citing works

Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers

Nakamura, M., Oshima, A., Fujimoto, Y., Maruyama, N., Ishibashi, T., & Reeves, K. R. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.012 · Cited by 185 · see citing works

A double-blind study evaluating the long-term safety of varenicline for smoking cessation

Williams, K. E., Reeves, K. R., Billing, C. B., Pennington, A. M., & Gong, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182185 · Cited by 184 · see citing works

Nicotine receptor partial agonists for smoking cessation

Cahill, K., Stead, L. F., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub6 · Cited by 177 · see citing works

Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease

Bullen, C. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.6.883 · Cited by 173 · see citing works

Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability

Fowler, C. D., & Kenny, P. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.09.008 · Cited by 167 · see citing works

Diretrizes para cessação do tabagismo - 2008

Reichert, J., Araújo, A. J. D., Gonçalves, C. M. C., Godoy, I., Chatkin, J. M., Sales, M. D. P. U., & Santos, S. R. R. D. A. (2008) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132008001000014 · Cited by 166 · see citing works

Central Nicotinic Receptors: Structure, Function, Ligands, and Therapeutic Potential

Romanelli, M. N., Gratteri, P., Guandalini, L., Martini, E., Bonaccini, C., & Gualtieri, F. (2007) · ChemMedChem · doi:10.1002/cmdc.200600207 · Cited by 164 · see citing works

Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence

Rollema, H., Shrikhande, A., Ward, K., Tingley III, F., Coe, J., O'Neill, B., Tseng, E., Wang, E., Mather, R., Hurst, R., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00682.x · Cited by 162 · see citing works

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Varenicline for Smoking Cessation in Patients With Schizophrenia or Schizoaffective Disorder

Williams, J. M., Anthenelli, R. M., Morris, C. D., Treadow, J., Thompson, J. R., Yunis, C., & George, T. P. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07522 · Cited by 162 · see citing works

Effects of Varenicline on Smoking Cue–Triggered Neural and Craving Responses

Franklin, T. R., Wang, Z., Suh, J. J., Hazan, R., Cruz, J., Li, Y., Goldman, M., Detre, J. A., O’Brien, C. P., & Childress, A. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.190 · Cited by 162 · see citing works

How Can We Use Our Knowledge of Alcohol-Tobacco Interactions to Reduce Alcohol Use?

McKee, S. A., & Weinberger, A. H. (2012) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185549 · Cited by 160 · see citing works

Cognitive enhancement as a pharmacotherapy target for stimulant addiction

Sofuoglu, M. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02791.x · Cited by 158 · see citing works

Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states

Picciotto, M. R., Lewis, A. S., van Schalkwyk, G. I., & Mineur, Y. S. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.028 · Cited by 157 · see citing works

The role of the habenula in drug addiction

Velasquez, K. M., Molfese, D. L., & Salas, R. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00174 · Cited by 155 · see citing works

Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis

Thomas, K. H., Dalili, M. N., López-López, J. A., Keeney, E., Phillippo, D., Munafo, M. R., Stevenson, M., Caldwell, D. M., & Welton, N. J. (2021) · Health Technology Assessment · doi:10.3310/hta25590 · Cited by 153 · see citing works

Effects of Moderate-Dose Treatment With Varenicline on Neurobiological and Cognitive Biomarkers in Smokers and Nonsmokers With Schizophrenia or Schizoaffective Disorder

Hong, L. E. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.83 · Cited by 150 · see citing works

(−)-Cytisine and Derivatives: Synthesis, Reactivity, and Applications

Rouden, J., Lasne, M., Blanchet, J., & Baudoux, J. (2013) · Chemical Reviews · doi:10.1021/cr400307e · Cited by 149 · see citing works

Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline: A Pooled Analysis

Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J. (2010) · Drug Safety · doi:10.2165/11319180-000000000-00000 · Cited by 142 · see citing works

Sazetidine-A, A Novel Ligand That Desensitizes α4β2 Nicotinic Acetylcholine Receptors without Activating Them

Xiao, Y., Fan, H., Musachio, J. L., Wei, Z.-L., Chellappan, S. K., Kozikowski, A. P., & Kellar, K. J. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027318 · Cited by 141 · see citing works

An insight into medicinal chemistry of anticancer quinoxalines

Kaushal, T., Srivastava, G., Sharma, A. K., & Negi, A. S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.11.021 · Cited by 140 · see citing works

Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice

Mineur, Y. S., Somenzi, O., & Picciotto, M. R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.01.006 · Cited by 137 · see citing works

Combination Varenicline and Bupropion SR for Tobacco-Dependence Treatment in Cigarette Smokers

Ebbert, J. O., Hatsukami, D. K., Croghan, I. T., Schroeder, D. R., ALLEN, S. S., Hays, J. T., & Hurt, R. D. (2014) · JAMA · doi:10.1001/jama.2013.283185 · Cited by 137 · see citing works

Effects of Varenicline and Bupropion Sustained-Release Use Plus Intensive Smoking Cessation Counseling on Prolonged Abstinence From Smoking and on Depression, Negative Affect, and Other Symptoms of Nicotine Withdrawal

Cinciripini, P. M., Robinson, J. D., Karam-Hage, M., Minnix, J. A., Lam, C., Versace, F., Brown, V. L., Engelmann, J. M., & Wetter, D. W. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.678 · Cited by 136 · see citing works

The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline: Varenicline For Treatment Of Nicotine Dependence

Foulds, J. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00955.x · Cited by 136 · see citing works

Effects of Varenicline on Smoking Cessation in Adults With Stably Treated Current or Past Major Depression

Anthenelli, R. M., Morris, C. D., Ramey, T. S., Dubrava, S., Tsilkos, K., Russ, C., & Yunis, C. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-6-201309170-00005 · Cited by 136 · see citing works

Treatment of nicotine addiction: present therapeutic options and pipeline developments

Polosa, R., & Benowitz, N. L. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.008 · Cited by 135 · see citing works

3D Molecular Descriptors Important for Clinical Success

Kombo, D. C., Tallapragada, K., Jain, R., Chewning, J., Mazurov, A. A., Speake, J. D., Hauser, T. A., & Toler, S. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300445e · Cited by 134 · see citing works

Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes

Ray, R., Tyndale, R. F., & Lerman, C. E. (2009) · Journal of Neurogenetics · doi:10.1080/01677060802572887 · Cited by 134 · see citing works

A randomized, placebo-controlled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers

Tsai, S.-T., Cho, H., Cheng, H., Kim, C.-H., Hsueh, K.-C., Billing, C. B., & Williams, K. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.011 · Cited by 134 · see citing works

Neuronal Nicotinic Acetylcholine Receptors: Common Molecular Substrates of Nicotine and Alcohol Dependence

Hendrickson, L. M., Guildford, M. J., & Tapper, A. R. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00029 · Cited by 132 · see citing works

Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior

Tuesta, L. M., Fowler, C. D., & Kenny, P. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.026 · Cited by 129 · see citing works

Varenicline for Tobacco Dependence

Hays, J. T., & Ebbert, J. O. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0800146 · Cited by 129 · see citing works

Update on Pharmacologic Options for Smoking Cessation Treatment

Nides, M. A. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.01.016 · Cited by 128 · see citing works

Cholinergic Modulation of Locomotion and Striatal Dopamine Release Is Mediated by 6 4* Nicotinic Acetylcholine Receptors

Drenan, R. M., Grady, S. R., Steele, A. D., McKinney, S., Patzlaff, N. E., McIntosh, J. M., Marks, M. J., Miwa, J. M., & Lester, H. A. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2056-10.2010 · Cited by 127 · see citing works

Nicotinic Activity of Arecoline, the Psychoactive Element of "Betel Nuts", Suggests a Basis for Habitual Use and Anti-Inflammatory Activity

Papke, R. L., Horenstein, N. A., & Stokes, C. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140907 · Cited by 127 · see citing works

Neurobiological Mechanisms of Nicotine Reward and Aversion

Wills, L. P., Ables, J. L., Braunscheidel, K. M., Caligiuri, S. P. B., Elayouby, K. S., Fillinger, C., Ishikawa, M., Moen, J. K., & Kenny, P. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000299 · Cited by 126 · see citing works

A preliminary investigation of varenicline for heavy drinking smokers

Fucito, L. M., Toll, B. A., Wu, R., Romano, D. M., Tek, E., & O’Malley, S. S. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2160-9 · Cited by 124 · see citing works

Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation

Tutka, P., Vinnikov, D. V., Courtney, R. J., & Benowitz, N. L. (2019) · Addiction · doi:10.1111/add.14721 · Cited by 123 · see citing works

Nicotinic acetylcholine receptors: Conventional and unconventional ligands and signaling

Papke, R. L., & Lindstrom, J. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108021 · Cited by 123 · see citing works

Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy.

Tutka, P., & Zatoński, W. A. (2006) · PubMed · Cited by 123 · see citing works

A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation

Faessel, H. M., Obach, R. S., Rollema, H., Ravva, P., Williams, K. E., & Burstein, A. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11537850-000000000-00000 · Cited by 120 · see citing works

Pharmacological interventions for promoting smoking cessation during pregnancy

Coleman, T. J., Chamberlain, C., Davey, M., Cooper, S. E., & Leonardi‐Bee, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010078 · Cited by 120 · see citing works

The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats

O’Connor, E. C., Parker, D., Rollema, H., & Mead, A. N. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1739-5 · Cited by 118 · see citing works

Preclinical pharmacology of the α4β2 nAChR partial agonist varenicline related to effects on reward, mood and cognition

Rollema, H., Hajós, M., Seymour, P. A., Kozak, R., Majchrzak, M. J., Guanowsky, V., Horner, W. E., Chapin, D. S., Hoffmann, W. E., Johnson, D. E., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.033 · Cited by 117 · see citing works

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials

King, D. P., Paciga, S. A., Pickering, E. H., Benowitz, N. L., Bierut, L. J., Conti, D. V., Kaprio, J. A., Lerman, C. E., & Park, P. W. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.232 · Cited by 117 · see citing works

Molecules and circuits involved in nicotine addiction: The many faces of smoking

Picciotto, M. R., & Mineur, Y. S. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.028 · Cited by 117 · see citing works

Current and emerging pharmacotherapies for treating tobacco dependence

Schnoll, R. A., & Lerman, C. E. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.429 · Cited by 117 · see citing works

Nicotine receptor partial agonists for smoking cessation

Cahill, K., Stead, L. F., & Lancaster, T. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub3 · Cited by 116 · see citing works

Varenicline-Induced Manic Episode in a Patient With Bipolar Disorder

Kohen, I., & Kremen, N. J. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010173 · Cited by 113 · see citing works

Pyrazine derivatives: a patent review (June 2012 – present)

Doležal, M., & Zítko, J. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.982533 · Cited by 112 · see citing works

Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial

Shim, J.-C., Jung, D.-U., Jung, S. S., Seo, Y.-S., Cho, D.-M., Lee, J.-H., Lee, S.-W., Kong, B.-G., Kang, J.-W., Oh, M., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.238 · Cited by 112 · see citing works

The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial

NIAURA, R. S., Hays, J. T., Jorenby, D. E., Leone, F. T., Pappas, J. E., Reeves, K. R., Williams, K. E., & Billing, C. B. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802177523 · Cited by 112 · see citing works

Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats

Bito‐Onon, J. J., Simms, J. A., Chatterjee, S., Holgate, J. Y., & Bartlett, S. E. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00309.x · Cited by 111 · see citing works

The Smoking Cessation Medication Varenicline Attenuates Alcohol and Nicotine Interactions in the Rat Mesolimbic Dopamine System

Ericson, M., Löf, E., Stomberg, R., & Söderpalm, B. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.147058 · Cited by 109 · see citing works

Microglia morphology and proinflammatory signaling in the nucleus accumbens during nicotine withdrawal

Adeluyi, A., Guerin, L. N., Fisher, M. L., Galloway, A. L., Cole, R. D., Chan, S. S. L., Wyatt, M. D., Davis, S. W., Freeman, L. R., Ortinski, P. I., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax7031 · Cited by 107 · see citing works

Pyridine alkaloids with activity in the central nervous system

Lin, S. X., Curtis, M. A., & Sperry, J. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115820 · Cited by 106 · see citing works

Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533 · see citing works

Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation

Rollema, H., Coe, J. W., Chambers, L. K., Hurst, R. S., Stahl, S. M., & Williams, K. E. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.05.003 · Cited by 400 · see citing works

Partial Nicotinic Acetylcholine (α4β2) Agonists as Promising New Medications for Smoking Cessation

Singh, J., & Budhiraja, S. (2009) · TSpace (University of Toronto)

The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline: Varenicline For Treatment Of Nicotine Dependence

Foulds, J. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00955.x · Cited by 136 · see citing works

Chapter 4 Case History: Chantix™/Champix™ (Varenicline Tartrate), a Nicotinic Acetylcholine Receptor Partial Agonist as a Smoking Cessation Aid

Coe, J. W., Rollema, H., & O’Neill, B. T. (2009) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(09)04404-2 · Cited by 22 · see citing works